New Vivalytic Viral Respiratory Tract Infection Array can identify SARS-CoV-2 virus

A game-changing point of care coronavirus test from global diagnostics company Randox Laboratories and leading technology manufacturer Bosch Healthcare Solutions will launch in April 2020.

The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.

This provides a more comprehensive respiratory screening which enables precise and informed treatment decisions to be made.

Dr. Heather McMillan, Molecular R&D Scientist at Randox Biosciences, commented;

This array focuses not only on the identification of the novel coronavirus strain that causes COVID-19, but also nine other respiratory infection targets simultaneously, including Influenza A and B, Sarbecovirus and MERS. The aim is to diagnose patients fast and accurately from a single genetic sample, maximizing containment of the virus whilst minimizing the spread. With the development of this array onto a fully automated platform, patients can be diagnosed rapidly at point of care locations globally such as pharmacies and doctor surgeries.”

The Viral Respiratory Tract Infection Array is one of the world’s first multiplex molecular diagnostic tests meeting the COVID-19 testing recommendations of the World Health Organisation (WHO) and the Centres for Disease Control (CDC).

The target gene for COVID-19 being used on the VRI array is ORF1ab, and for Sarbecovirus (SARS, SARS like, SARS-CoV-2) is E gene, representing conserved regions of the genome which have been chosen for their high sensitivity and specificity.

Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said:

We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”

The new VRI test will be conducted on Vivalytic a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed which minimizes the risk of contamination, require room temperature storage (space-saving), contain all the reagents on-board the cartridge and utilizes end point PCR.  The test only requires a single nasal swab from the patient and an easy four step process to be carried out by the user to run the patient sample.

Sample Type: Nasopharyngeal Swab

Sample Volume: 300 µl clinical sample

Key Benefits of Vivalytic | Point of Care Platform

  • Fully-automated
  • User friendly
  • No laboratory training required
  • 4 step work flow
  • Minimal contamination risk – fully contained system
  • No peripherals required – hygienic
  • Touchscreen
  • Connects to LIMS (Laboratory Information Management System)
Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Randox. (2020, April 01). New Vivalytic Viral Respiratory Tract Infection Array can identify SARS-CoV-2 virus. News-Medical. Retrieved on June 06, 2020 from https://www.news-medical.net/news/20200401/New-Vivalytic-Viral-Respiratory-Tract-Infection-Array-can-identify-SARS-CoV-2-virus.aspx.

  • MLA

    Randox. "New Vivalytic Viral Respiratory Tract Infection Array can identify SARS-CoV-2 virus". News-Medical. 06 June 2020. <https://www.news-medical.net/news/20200401/New-Vivalytic-Viral-Respiratory-Tract-Infection-Array-can-identify-SARS-CoV-2-virus.aspx>.

  • Chicago

    Randox. "New Vivalytic Viral Respiratory Tract Infection Array can identify SARS-CoV-2 virus". News-Medical. https://www.news-medical.net/news/20200401/New-Vivalytic-Viral-Respiratory-Tract-Infection-Array-can-identify-SARS-CoV-2-virus.aspx. (accessed June 06, 2020).

  • Harvard

    Randox. 2020. New Vivalytic Viral Respiratory Tract Infection Array can identify SARS-CoV-2 virus. News-Medical, viewed 06 June 2020, https://www.news-medical.net/news/20200401/New-Vivalytic-Viral-Respiratory-Tract-Infection-Array-can-identify-SARS-CoV-2-virus.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Randox's Acusera Immunoassay Speciality 1 quality control receives FDA clearance